Spyre Therapeutics (SYRE) Operating Leases (2019 - 2023)
Spyre Therapeutics' (SYRE) quarterly Operating Leases came in at $3.8 million in Q1 2023, down 14.42% YoY from $4.5 million in Q1 2022, and down 4.52% on a QoQ basis from $4.0 million in Q4 2022.
Spyre Therapeutics (SYRE) Operating Leases (2019 - 2023) Analysis & Trends
Spyre Therapeutics (SYRE) has 5 years of Operating Leases data on file, last reported at $3.8 million in Q1 2023.
- Quarterly Operating Leases fell 14.42% year-over-year to $3.8 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $3.8 million (down 14.42% YoY) and the FY2022 annual result came in at $4.0 million, down 13.11% from the prior year.
- Operating Leases slipped to $3.8 million in Q1 2023, from $4.0 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $5.1 million in Q4 2020 to a low of $372000.0 in Q1 2019.
- A 5-year average of $4.4 million and a median of $4.7 million in 2019 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2020 — Operating Leases soared 1194.35% — and 2023, when it retreated 14.42%.
- Tracing SYRE's Operating Leases over 5 years: stood at $4.7 million in 2019, then advanced by 8.85% to $5.1 million in 2020, then slipped by 10.16% to $4.6 million in 2021, then dropped by 13.11% to $4.0 million in 2022, then fell by 4.52% to $3.8 million in 2023.
- The last three Operating Leases figures came in at $3.8 million (Q1 2023), $4.0 million (Q4 2022), and $4.2 million (Q3 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Spyre Therapeutics | 9.13 Bn | 9.13 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 3.82 Mn |
| Dec 31, 2022 | 4.00 Mn |
| Sep 30, 2022 | 4.16 Mn |
| Jun 30, 2022 | 4.32 Mn |
| Mar 31, 2022 | 4.47 Mn |
| Dec 31, 2021 | 4.61 Mn |
| Sep 30, 2021 | 4.75 Mn |
| Jun 30, 2021 | 4.88 Mn |
| Mar 31, 2021 | 5.01 Mn |
| Dec 31, 2020 | 5.13 Mn |
| Sep 30, 2020 | 4.95 Mn |
| Jun 30, 2020 | 4.70 Mn |
| Mar 31, 2020 | 4.82 Mn |
| Dec 31, 2019 | 4.71 Mn |
| Sep 30, 2019 | 4.87 Mn |
| Jun 30, 2019 | 4.82 Mn |
| Mar 31, 2019 | 372,000.00 |